Maria Sharapova announced that she failed a drug test at the Australian Open in January. The future of the 28-year-old superstar will now be handled by the Women’s Tennis Association which governs women’s tennis. CBSN’s Vladimir Duthiers has the latest.
Maria Sharapova announced Monday that she tested positive for a medication her physician prescribed. The drug meldonium is clinically used to treat angina and myocardial infarction.
The first clinical trial in 2005 tested the efficacy of using a combination of meldonium and lisinopril, an angiotensin-converting enzyme inhibitor, to treat chronic heart failure was reported in 2005. The report concluded that the combined treatment of meldonium and lisinopril may improve quality of life, exercise capacity and mechanisms of peripheral circulation of patients with chronic heart failure.
Meldonium is not approved for drug use by the US FDA, and Meldonium was added to the World Anti-Doping Agency (WADA) list of banned substances on September 16, 2015 to be effective starting January 1, 2016. Several other athletes involved in endurance sports have also tested positive for meldonium.
Get updates from The Cardinal ALL NEWS FEEDS on Facebook. Just ‘LIKE’ the ‘Arlington Cardinal Page (become a fan of our page). The updates cover all posts and sub-category posts from The Cardinal — Arlingtoncardinal.com. You can also limit feeds to specific categories. See all of The Cardinal Facebook fan pages at Arlingtoncardinal.com/about/facebook …